Ceci est une version HTML d'une pièce jointe de la demande d'accès à l'information 'European Commission protocols for dealing with the tobacco industry'.





Document 15
Ref. Ares(2017)6186065 - 18/12/2017
From: 
NOWAK Annika (CAB-ANDRIUKAITIS) 
Sent: 
18 December 2017 10:32 
To: 
CAB ANDRIUKAITIS ARCHIVES 
Subject: 
FW: Request for a meeting / 23 & 24 January - Brussels 
Thanks! 
From: 
.
@sanofi.com [mailto:
.
@sanofi.com]  
Sent: Monday, December 18, 2017 10:30 AM 
To: NOWAK Annika (CAB-ANDRIUKAITIS) 
Subject: Request for a meeting / 23 & 24 January - Brussels 
Dear Mrs Nowak, Dear Annika, 
I am writing to you regarding the following point. 
 who is 
 from Sanofi in Germany, will be in Brussels on 23 & 24 
January 2018. 
He would very much appreciate to have the opportunity to meet you and to have an exchange 
of view, notably about the current evolution of the healthcare system and the place of Medical 
Science in Germany and the possibility to develop at the EU level a new concrete dialogue 
between actors to foster EU medical research, ease patient access and retain an innovativee Life 
Sciences sector in Europe. 
We believe that these goals can only be achieved thrrough a consttructive dialogue with Europe’s 
key decision makers.  
As Member of the Cabinet of Vytenis Andriukaitis, Commissionerr Health, you play a key role for 
the EU
, notably to find better regulation for a new constructive Europe . Your advices and 
knowledge would be important for us in the perspective to bring to you some win-win 
proposals.   
We hope that your schedule will allow you to meet 
 on 23 or 24 January. 
Thank you very much in advance, 
Kind regards, 
 European Public Affairs 
Tel: +32.
 Mob: +32.
Rue de la Science, 14 - 1040 Brussels – Belgium 
EU Transparency Register : 61291462764-77 
sanofi.com

Please consider the environment before printing this email! 
  
 
 
 
This communication, including any attachments, is intended solely for the use of the addressee and may contain 
information which is privileged, confidential, exempt from disclosure under applicable law or subject to copyright. If you 
are not an intended recipient, any use, disclosure, distribution, reproduction, review or copying is unauthorized and 
strictly prohibited. If you have received this e-mail in error, please notify the sender immediately and then destroy it 

without copying or disclosing its contents to any other person. Sanofi Belgium does not guarantee the correct and 
complete transmission of an e-mail sent, nor the timely receipt thereof. Any views or opinions presented are solely 
those of the author and do not necessarily represent those of Sanofi Belgium.  

Document Outline